Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.
Benjamin Solomon, MBBS, PhD, consultant medical oncologist, professor, group leader, Molecular Therapeutics and Biomarkers Laboratory, Research Division, Peter MacCallum Cancer Center, discusses the intracranial responses observed in the CROWN trial of lorlatinib (Lorbrena) versus crizotinib (Xalkori) in patients with ALK-positive non–small cell lung cancer (NSCLC).
The intracranial activity seen with lorlatinib was 1 of the most important findings in this phase 3 study, according to Solomon. All the patients on the trial received baseline MRIs and serial assessments of disease in the brain with subsequent MRI scans which were independently reviewed.
In patients with measurable brain metastases, the intracranial objective response rate by independent review was 82% with lorlatinib compared with 23% with crizotinib. The intracranial complete response rate was 71% with lorlatinib in these patients with ALK-positive NSCLC.
The time to intracranial progression showed a hazard ratio of 0.70. Solomon says this is a remarkable result and speaks to the ability of lorlatinib in its ability to not only delay progression of existing metastases, but also potentially prevent the development of new brain metastases.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More